NanoView Biosciences and Quantum Design Korea Enter Into Distribution Agreement

World News: . []

NanoView Biosciences, Inc., and Quantum Design Korea, a subsidiary of Quantum Design International, today announced an exclusive distribution agreement for NanoView’s ExoView™ platform in South Korea.

“We are eager to make NanoView’s unique technology for analyzing and characterizing exosomes available to scientists in Korea,” said Manwoong Nam, General Manager of Quantum Design Korea. “We have an excellent relationship with the NanoView team and look forward to developing that further for the benefit of our customers in this important research market.”

The ExoView platform provides high-resolution sizing, counting, and phenotyping of exosomes at the individual extracellular vesicle level. The molecular cargo carried by exosomes has potential for diagnostic, prognostic, and even therapeutic use for a broad range of diseases. The ExoView platform requires low sample input, no sample prep or purification, and minimal hands-on time. It can be used directly with complex biological samples.

“We are excited to team up with Quantum Design Korea, our second distribution agreement this year in Asia,” said Jerry Williamson, CEO of NanoView Biosciences. “Expanding access to our ExoView platform is essential for moving the entire exosome field forward, as our technology continues to be the only means of accurately characterizing these extracellular vesicles today.”

The ExoView platform is designed For Research Use Only. It is not for use in diagnostic procedures.

About NanoView Biosciences

NanoView Biosciences, a Boston-based, privately-held company, is focused on enabling life science researchers to better understand the biological role of exosomes and their potential use as biomarkers for improving the diagnosis, prognosis, treatment, and monitoring of disease. The company’s proprietary product, the ExoView™ platform, was designed to fully characterize exosomes and other extracellular vesicles for use in research and in the implementation of precision medicine. ExoView is a high-throughput, cost-effective analysis platform that is easy to use and does not require purification or large sample volumes to accurately analyze exosomes.


More news and information about NanoView Biosciences, Inc.

Published By:

Business Wire: 13:00 GMT Wednesday 11th September 2019

Published: .

Search for other references to "nanoview" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us